BC has traditionally been classified based on tumor size, regional lymph node infiltration, histology, grade, and immunohistochemical evaluation of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and proliferation marker Ki-67 [4, 5]. This evidence concerns the gene ERBB2 and breast cancer.